title: Novel drug delivery systems for releasing growth factors to the CNS: focus on Alzheimer's and Parkinson's diseases.
abstract: Alzheimer's disease (AD) and Parkinson's disease (PD) represent the most common neurodegenerative disorders and affect more than 35 million people. Due to the limited effectiveness of available treatments in halting the neurodegenerative process, new therapies, such therapies based on growth factors (GFs), have been investigated. Nevertheless, the efficacies of these new treatments depend not only on the application of neurotrophins but also on the approaches used to deliver these proteins such that they can reach the brain. This review summarises the most widely used drug delivery systems (DDSs) for releasing GFs as possible treatments for AD and PD.
authors: E
authors: E
authors: Herran
authors: M
authors: M
authors: Igartua
authors: J L
authors: JL
authors: Pedraz
authors: NanoBioCel Group, Laboratory of Pharmaceutics, University of the Basque Country (UPV/EHU), School of Pharmacy, Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain. rosa.hernandez@ehu.es.
authors: R M
authors: RM
authors: Hernandez
mesh_terms: D000544:Alzheimer Disease / Q000378:metabolism* / Q000628:therapy; D000818:Animals; D002490:Central Nervous System / Q000378:metabolism*; D016503:Drug Delivery Systems; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000008:administration & dosage* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D010300:Parkinson Disease / Q000378:metabolism* / Q000628:therapy
chemical_list: D036341:Intercellular Signaling Peptides and Proteins